期刊文献+

Viral hepatitis: A global burden needs future directions for the management

下载PDF
导出
摘要 Viral hepatitis is an acute or chronic liver disease due to the infection from Hepatitis A,B,C,D and E viruses.It can cause severe liver damage such as cirrhosis,liver failure and liver cancer.To avoid such fatal complications,hepatitis patients must be diagnosed,pathologized and treated as soon as possible.Furthermore,these hepatitis viruses infect through different routes,resulting in distinct disease pathologies,severity and even the need for specific treatment strategies to combat the infection.
出处 《World Journal of Gastroenterology》 SCIE CAS 2022年第16期1718-1721,共4页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献4

二级参考文献107

  • 1Mohammad Irshad,Dhananjay Singh Mankotia,Khushboo Irshad.An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World Journal of Gastroenterology,2013,19(44):7896-7909. 被引量:56
  • 2Vincenza Calvaruso,Antonio Craxì.Immunological alterations in hepatitis C virus infection[J].World Journal of Gastroenterology,2013,19(47):8916-8923. 被引量:12
  • 3Chun-Yan Yeung,Hung-Chang Lee,Wai-Tao Chan,Chun-Bin Jiang,Szu-Wen Chang,Chih-Kuang Chuang.Vertical transmission of hepatitis C virus: Current knowledge and perspectives[J].World Journal of Hepatology,2014,6(9):643-651. 被引量:6
  • 4World Health Organization. Hepatits B. Fact sheet No. 204.Available from: URL: http://wwwwhoint/mediacentre/facsheets/fs204/en 2014.
  • 5García-Fulgueiras A, García-Pina R, Morant C, García-Ortuzar V,Génova R, Alvarez E. Hepatitis C and hepatitis B-related mortalityin Spain. Eur J Gastroenterol Hepatol 2009; 21: 895-901 [PMID:19357523 DOI: 10.1097/MEG.0b013e328313139d].
  • 6Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP,Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T,Desenclos JC, Jougla E. Mortality related to chronic hepatitis Band chronic hepatitis C in France: evidence for the role of HIVcoinfection and alcohol consumption. J Hepatol 2008; 48: 200-207[PMID: 18086507 DOI: 10.1016/j.jhep.2007.09.010].
  • 7Adam R, Karam V, Delvart V, O'Grady J, Mirza D, KlempnauerJ, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S,Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, BurroughsA. Evolution of indications and results of liver transplantation inEurope. A report from the European Liver Transplant Registry(ELTR). J Hepatol 2012; 57: 675-688 [PMID: 22609307 DOI:10.1016/j.jhep.2012.04.015].
  • 8European Association For The Study Of The Liver. EASLclinical practice guidelines: Management of chronic hepatitis Bvirus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845DOI: 10.1016/j.jhep.2012.02.010].
  • 9Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H,Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF,Sabbat J. Lamivudine for patients with chronic hepatitis B andadvanced liver disease. N Engl J Med 2004; 351: 1521-1531[PMID: 15470215 DOI: 10.1056/NEJMoa033364].
  • 10Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, KlempnauerJ, Manns MP. Lamivudine and low-dose hepatitis B immuneglobulin for prophylaxis of hepatitis B reinfection after livertransplantation possible role of mutations in the YMDD motif priorto transplantation as a risk factor for reinfection. J Hepatol 2001;34: 895-902 [PMID: 11451174].

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部